Preclinical evidence also shows that TIGIT is often co-expressed with PD-1 on tumour-specific CD8+ T cells, and combined TIGIT/PD-1 blockade may enhance anti-tumour activity [198]. This evidence concerns the gene CD8A and neoplasm.